Glucose Health, Inc. Fiscal
2021 Revenue Up 110% For Nine Month Period Ended September 30,
2021
BENTONVILLE, Arkansas -- November 3, 2021 -- Glucose Health,
Inc. (OTC:
"GLUC") ("Company") is pleased to highlight key financial
information detailed in its Fiscal 2021 Third Quarter Report, for
the period ending September 30, 2021, posted at OTCMarkets.com.
- Nine Month Fiscal 2021 Revenue of $759,498 vs. $361,256 for
Nine Month Fiscal 2020 – an increase of 110%
- Q3 Fiscal 2021 Revenue of $234,930 vs. $126,504 for Q3 Fiscal
2020 – an increase of 86%
- Nine Month Fiscal 2021 Gross Profit of $279,748 vs. $165,265
for YTD Fiscal 2020 – an increase of 69%
- Q3 Fiscal 2021 Gross Profit of $85,714 vs. $68,379 for Q3
Fiscal 2020 – an increase of 25%
GLUCODOWN® continues to enjoy increasingly popularity among
consumers as evidenced by outstanding sales and reviews at
Amazon. In total, many thousands of reviews have been
published at Amazon, with seven of eight flavors of GLUCODOWN®
receiving 4.5-star ratings. Additionally, all
double-packs receive 4.5 and 5 star
reviews. Customers most often identify health benefits
and delicious taste, as the reasons for satisfaction with
purchasing GLUCODOWN®.
Additionally, during this quarter, the Glucose Health, Inc. will
provide a progress report regarding its enterprise value enhancing,
intellectual property initiative, first referenced in the Company's
January 4, 2021, press release.
About Glucose Health, Inc. (OTC:
GLUC)
With a focus on creating delicious beverages nutritionally
appropriate1 for the nation's 100+ million2 pre and
Type-2 diabetics, Glucose Health, Inc., the manufacturer of
GLUCODOWN®, is uniquely positioned among all emerging beverage
companies in America. Introduced in the third quarter of 2018, the
GLUCODOWN® brand has established itself as the market leader for an
entirely new category – functional, diabetic friendly, beverages.
Glucose Health, Inc. is a publicly traded company with the ticker
symbol OTC: GLUC.
To buy GLUCODOWN® visit our Amazon Store at
www.amazon.com/glucodown
Like us on Facebook at www.facebook.com/glucodown
For more GLUC information visit www.glucosehealthinc.com
1 For citations visit
www.glucodown.com/clinical-data
2 National Diabetes
Statistics Review, 2020; Centers for Disease Control and
Prevention, Department of Health and Human Services
This news release contains forward-looking statements within the
meaning of Section 27A of the Securities Act of 1933, as amended,
and while Glucose Health, Inc. is not subject to the 1934
Securities and Exchange Act, contains forward-looking statements
within the meaning Section 21E of the Securities and Exchange Act
of 1934, as amended. Statements that are not a description of
historical facts constitute forward-looking statements and may
often, but not always, be identified by the use of such words as
"expects," "anticipates," "intends," "estimates," "plans,"
"potential, "possible," "probable, "believes," "seeks," "may,
"will, "should," "could" or the negative of such terms or other
similar expressions. Actual results may differ materially from
those set forth in this release due to the risks and uncertainties
inherent in the Company's business. Readers are cautioned not to
place undue reliance on these forward-looking statements, which
speak only as of the date hereof. All forward-looking statements
are qualified in their entirety by this cautionary statement and
the Company undertakes no obligation to revise or update this
release to reflect events or circumstances after the date
hereof.
Contact:
Murray Fleming
Glucose Health, Inc.
info@glucosehealthinc.com
(479) 802-3827